Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: BONE REMODELING - DRUG EFFECTS , . Treffer: 20

2017

Fahrleitner-Pammer, A; Wagner, D; Krisper, P; Amrein, K; Dimai, H Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report.
Osteoporos Int. 2017; 28(3):1149-1152 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schwetz, V; Schnedl, C; Urbanic-Purkart, T; Trummer, C; Dimai, HP; Fahrleitner-Pammer, A; Putz-Bankuti, C; Christopher, KB; Obermayer-Pietsch, B; Pieber, TR; Dobnig, H; Amrein, K Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.
Osteoporos Int. 2017; 28(12):3347-3354 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schwetz, V; Trummer, C; Pandis, M; Grübler, MR; Verheyen, N; Gaksch, M; Zittermann, A; März, W; Aberer, F; Lang, A; Treiber, G; Friedl, C; Obermayer-Pietsch, B; Pieber, TR; Tomaschitz, A; Pilz, S Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial.
Nutrients. 2017; 9(5): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Tsourdi, E; Langdahl, B; Cohen-Solal, M; Aubry-Rozier, B; Eriksen, EF; Guañabens, N; Obermayer-Pietsch, B; Ralston, SH; Eastell, R; Zillikens, MC Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Bone. 2017; 105(21-22):11-17
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Grübler, MR; Meinitzer, A; Trummer, C; Schwetz, V; Amrein, K; Dimai, HP; März, W; Catena, C; von Lewinski, D; Voelkl, J; Alesutan, I; Fahrleitner-Pammer, A; Brussee, H; Pilz, S; Tomaschitz, A Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Bone. 2017; 105(5):212-217
Web of Science PubMed FullText FullText_MUG

 

2016

Fahrleitner-Pammer, A; Burr, D; Dobnig, H; Stepan, JJ; Petto, H; Li, J; Krege, JH; Pavo, I Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Bone. 2016; 89(6):16-24 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Muschitz, C; Kocijan, R; Pahr, D; Patsch, JM; Amrein, K; Misof, BM; Kaider, A; Resch, H; Pietschmann, P Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Calcif Tissue Int. 2015; 96(6): 477-489.
Web of Science PubMed FullText FullText_MUG

 

2013

Kerschan-Schindl, K; Haschka, J; Obermayer-Pietsch, B; Gasser, RW; Dimai, HP; Fahrleitner-Pammer, A; Dobnig, H; Roschger, P; Preisinger, E; Klaushofer, K; Resch, H; Pietschmann, P How long should women with postmenopausal osteoporosis be treated with a bisphosphonate?
Horm Metab Res. 2013; 45(9):621-628
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Lung, S; Resch, H Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
J Bone Miner Res. 2013; 28(1):196-205 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Wagner, D; Amrein, K; Dimai, HP; Kniepeiss, D; Tscheliessnigg, KH; Kornprat, P; Dobnig, H; Pieber, T; Fahrleitner-Pammer, A Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
Transplantation. 2012; 93(3):331-336 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Henneicke, H; Herrmann, M; Kalak, R; Brennan-Speranza, TC; Heinevetter, U; Bertollo, N; Day, RE; Huscher, D; Buttgereit, F; Dunstan, CR; Seibel, MJ; Zhou, H Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism.
Bone. 2011; 49(4):733-742
Web of Science PubMed FullText FullText_MUG

 

Quesada-Gómez, JM; Muschitz, C; Gómez-Reino, J; Greisen, H; Andersen, HS; Dimai, HP The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
Osteoporos Int. 2011; 22(9): 2529-2537.
Web of Science PubMed FullText FullText_MUG

 

2010

Stepan, JJ; Burr, DB; Li, J; Ma, YL; Petto, H; Sipos, A; Dobnig, H; Fahrleitner-Pammer, A; Michalská, D; Pavo, I Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Osteoporos Int. 2010; 21(12): 2027-2036.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2009

Cummings, SR; San Martin, J; McClung, MR; Siris, ES; Eastell, R; Reid, IR; Delmas, P; Zoog, HB; Austin, M; Wang, A; Kutilek, S; Adami, S; Zanchetta, J; Libanati, C; Siddhanti, S; Christiansen, C; FREEDOM Trial Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009; 361(8): 756-765. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Friedl, G; Turner, RT; Evans, GL; Dobnig, H Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism.
J Orthop Res. 2007; 25(11): 1454-1464. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Herrmann, M; Umanskaya, N; Traber, L; Schmidt-Gayk, H; Menke, W; Lanzer, G; Lenhart, M; Peter Schmidt, J; Herrmann, W The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial.
Clin Chem Lab Med. 2007; 45(12):1785-1792
Web of Science PubMed FullText FullText_MUG

 

2006

Dobnig, H; Hofbauer, LC; Viereck, V; Obermayer-Pietsch, B; Fahrleitner-Pammer, A Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Osteoporos Int. 2006; 17(5):693-703
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Herrmann, M; Stanger, O; Paulweber, B; Hufnagl, C; Herrmann, W Folate supplementation does not affect biochemical markers of bone turnover.
Clin Lab. 2006; 52(3-4):131-136
Web of Science PubMed

 

2002

Reid, IR; Brown, JP; Burckhardt, P; Horowitz, Z; Richardson, P; Trechsel, U; Widmer, A; Devogelaer, JP; Kaufman, JM; Jaeger, P; Body, JJ; Brandi, ML; Broell, J; Di Micco, R; Genazzani, AR; Felsenberg, D; Happ, J; Hooper, MJ; Ittner, J; Leb, G; Mallmin, H; Murray, T; Ortolani, S; Rubinacci, A; Saaf, M; Samsioe, G; Verbruggen, L; Meunier, PJ Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
N Engl J Med. 2002; 346(9):653-661 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1998

Dimai, HP; Porta, S; Wirnsberger, G; Lindschinger, M; Pamperl, I; Dobnig, H; Wilders-Truschnig, M; Lau, KH Daily oral magnesium supplementation suppresses bone turnover in young adult males.
J Clin Endocrinol Metab. 1998; 83(8):2742-2748 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Meduni Graz Impressum